Thailand Precision Medicine Market Advances: Hospitals Push Personalized Care With Genomics

Hospitals are also building capabilities around next-generation sequencing (NGS) as whole-exome sequencing (WES) and whole-genome sequencing (WGS) become increasingly utilized in medical services. The Excellence Center for Genomics and Precision Medicine at King Chulalongkorn Memorial Hospital evolved from the Excellence Center of Medicine Genetics, reflecting the ongoing expansion of genetics and genomics work. A concrete example of clinical implementation is the partnership between BC Platforms and Bumrungrad International Hospital. BC Platforms announced an expanded partnership in October 2021, building on an initial partnership formed in February 2019. The expanded work supports clinical sample management and automated workflows for genotype-based wellness reporting and NGS-based neonatal screening, using a Personalized Medicine Platform powered by BC|GENOME for germline and somatic tumor testing.

Genomics and National Programs Strengthen the Pipeline

The genomics market outlook aligns with this hospital momentum. Grand View Research estimates Thailand’s genomics market generated USD 49.5 million in 2025 and is expected to reach USD 147.4 million by 2033, with an expected CAGR of 16.5% from 2026 to 2033. Functional genomics was the largest application in 2025, holding a 33.74% revenue share, while pathway analysis is expected to be the most lucrative and fastest-growing application segment. In 2025, Thailand accounted for 0.2% of the genomics market by revenue. The same source links Thailand’s position as a growing hub to increasing government investments and projects, including the Genomics Thailand Initiative launched in 2019 and the National Biobank of Thailand (NBT) established in 2019, alongside a Southeast Asian genome-sequencing project.

Demand drivers also connect to Thailand’s disease burden and the need for better diagnosis and treatment selection. Grand View Research reports that cancer prevalence has increased and accounts for 19% of overall deaths in Thailand, followed by 12% of deaths due to ischemic heart disease and 10% due to stroke. The report also cites rising incidence of infectious diseases including hepatitis, diarrhea, dengue fever, malaria, Japanese encephalitis, HIV, leptospirosis, and rabies, which is expected to fuel demand for genome sequencing technologies for diagnosis and treatment. On the personalized medicine side, Grand View Research notes that the Genomics Thailand Initiative aims to sequence 50,000 Thai individuals across five disease groups: cancers, rare diseases, noncommunicable diseases, infectious diseases, and pharmacogenomics. In addition, personalized nutrition and wellness led Thailand’s personalized medicine market segments with a 35.32% revenue share in 2024.

Analytics and AI are becoming practical enablers for clinical adoption, not just research tools. Ken Research values the Thailand AI life science analytics market at USD 15 million, based on a five-year historical analysis, and links growth to AI integration in drug discovery, patient management, and the rising demand for personalized medicine and data management. It also states that the National AI Strategy 2022–2027, issued in 2022, promotes AI in healthcare through targeted investments exceeding THB 500 million, along with mandatory compliance requirements for public sector AI deployments, including data security standards, and incentives for private-sector adoption in diagnostics and analytics. In practice, these forces support the Thailand precision medicine market story: hospitals are pairing NGS-driven testing with stronger data infrastructure, so personalized care can be delivered through repeatable workflows rather than one-off cases.